We sincerely welcome Dr. Fady Alnajjar from United Arab Emirates University, UAE, to join the Editorial Board of OBM Neurobiology. Dr. Alnajjar is an Associate Professor of the Department of Computer Science and Software Engineering at United Arab Emirates University. He has extensive experience in signal processing, behavior analysis, motor learning and motor control, artificial intelligence, brain, rehabilitation robotics, neural networks, and cognitive training. We are grateful to Dr. Alnajjar for his participation and support.

We sincerely welcome Dr. Sergey Bachurin the full member of Russian Academy of Sciences, Russian Federation, to join the Editorial Board of OBM Neurobiology. He has completed his PhD and Dr. Sci. Degree in Moscow State University, Russia. In 1992 and in 1995 he had been working in the University San Francisco and in Taft’s University (USA). Since 2006 till 2019 he was a director of the Institute of Physiologically Active Compounds, Russian Academy of Science in Chernogolovka, Russia. Since 2001 till present he is the Head of Department of Medicinal and Biological Chemistry of the IPAC RAS. He has published more than 250 papers in reputed journals and about 40 patents, and has been serving as an editorial board member of repute. We appreciate Dr. Sergey Bachurin for his participation and support.

We sincerely welcome Dr. Iain P Hargreaves from Liverpool John Moores University, UK, to join the Editorial Board of OBM Neurobiology. Dr. Iain P Hargreave is an expert in neuroscience and mitochondrial disease. He has more than 180 publications. We appreciate Dr. Iain P Hargreaves for his participation and support.

We sincerely welcome Dr. Maurizio Elia from IRCCS Oasi Maria SS., Italy, to join the Editorial Board of OBM Neurobiology. His main research interests are electroencephalography, neurology, epilepsy, and brain. We appreciate Dr. Maurizio Elia for his participation and support.

It is our pleasure to announce that LIDSEN has joined the ORCID community. ORCID (Open Researcher and Contributor ID), a global, not-for-profit organization, provides a free, unique, and persistent digital identifier (an ORCID iD), which can automatically link researchers to their own contributions, so as to disambiguate researchers from one another. Authors who publish with OBM Neurobiology are greatly encouraged to register for a unique iD to ensure proper attribution.

We sincerely welcome Prof. Dr. Najam Sharif, from Global Alliance and External Research, Santen Inc., USA, to join the Editorial Board of OBM Neurobiology. Dr. Sharif, PhD, DSc has >34-years’ pharmaceutical drug discovery research/development experience covering neuroscience and ophthalmology. His 22-year tenure at Alcon resulted in his contributions to the discovery, characterization, development and US FDA approvals of Patanol®/Pataday®/Pazeo® and Emadine® to treat allergic conjunctivitis, and Travatan® and Simbrinza® for the treatment of ocular hypertension / Glaucoma. Currently, he is Vice President, Global Alliances and External Research, Ophthalmology Innovation Center at Santen Inc USA, where he has been instrumental in establishing, nurturing and managing long term partnerships with pharma companies and several global universities. Dr. Sharif serves on numerous committees of many learned Societies (including ISER, elected Trustee of AOPT & Gold Fellow; Gold Fellow of ARVO and Fellow of British Pharmacological Society (BPS)). Dr. Sharif is Editor/Associate Editor/Editorial Board member of many Pharmacology and Ophthalmic journals. He is the recipient of the inaugural Dr. Roger Vogel award for ocular pharmaceutical research (ARVO Foundation, 2104), the recipient of the “Sir James Black Award” for contributions to drug discovery (BPS, 2017), and awardee of the Ernst Barany Prize for outstanding contributions to ocular pharmacology. Dr. Sharif is an Adjunct Professor / Honorary Senior Lecturer / Senior Principal Investigator and graduate Faculty at multiple Universities worldwide. He has also been a PhD-candidates’ supervisor, advisor and mentor to several students at numerous academic institutions. Dr. Sharif has published >215 scientific articles, edited 3 books, holds 24 issued US/EU patents, and has filed >30 patent applications over the last two decades.We appreciate Dr. Sharif for his participation and support.

We sincerely welcome Dr. Thomas H.J. Burne, from University of Queensland, Australia, to join the Editorial Board of OBM Neurobiology. Dr. Burne has abundant professional experience in neuropsychiatric diseases, animal models, biological psychiatry, neuroanatomy, molecular biology, schizophrenia, behavioural neuroscience, et al. We appreciate Dr. Burne for his participation and support.

We sincerely welcome Dr. Khue Vu Nguyen, from University of California, USA, to join the Editorial Board of OBM Neurobiology. Dr. Nguyen has abundant professional experience in molecular biology, genetic diseases, enzymology, biosensors, biopolymers, neurodevelopmental and neurodegenerative disorders, cancer, etc. We appreciate Dr. Nguyen for his participation and support.

We sincerely welcome Dr. Jasmin from University of California San Francisco, United States, to join the Editorial Board of OBM Neurobiology. Dr. Jasmin has extensive experience in: pain, stress, theentericnervous system, primary sensory neurons, dorsal root ganglion, pharmacology, GABA, glutamate, TRPM8, and health care economics and policies, etc. We are sincerely grateful to Dr. Jasmin for his participation and support.

We sincerely welcome Dr. Khan from University of Tennessee Health Science Center, United States, to join the Editorial Board of OBM Neurobiology. Dr. Khan has extensive experience in: neuroscience, pharmacology, neurodegeneration, neuroinflammation, Parkinson’s disease, stroke; Alzheimer’s disease, multiple sclerosis and traumatic brain injury, etc. We are sincerely grateful to Dr. Khan for his participation and support.